Response to the feasibility of Kreher et al's "Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: methotrexate, alkylating agents, biologics, and small molecule inhibitors"
- PMID: 37379901
- DOI: 10.1016/j.jaad.2023.05.095
Response to the feasibility of Kreher et al's "Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: methotrexate, alkylating agents, biologics, and small molecule inhibitors"
Keywords: basal cell carcinoma; immunosuppression; inflammatory bowel disease; keratinocyte skin cancer; nonmelanoma skin cancer; primary skin cancer; psoriasis; rheumatoid arthritis; skin cancer screening; squamous cell carcinoma.
Conflict of interest statement
Conflicts of interest Dr Mansh is supported by the National Institute of Environmental Health Sciences (U01ES029603). The content of this article does not necessarily represent the official view of the National Institutes of Health but is the sole responsibility of the authors. Dr Goldfarb has participated in clinical trials with AbbVie, Pfizer, Chemocentryx, and DeepX Health, and has served on advisory boards and consulted for Novartis and Boehringer Ingelheim. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of any other companies or organizations. Author Rypka has no conflicts of interest to declare.
Comment on
-
Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: Methotrexate, alkylating agents, biologics, and small molecule inhibitors.J Am Acad Dermatol. 2023 Mar;88(3):534-542. doi: 10.1016/j.jaad.2022.11.043. Epub 2022 Nov 30. J Am Acad Dermatol. 2023. PMID: 36460256 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous